Peer-reviewed veterinary case report
Rush sublingual immunotherapy reduces itching in dogs with atopic
By Fujimura, M & Ishimaru, H·Published in Polish journal of veterinary sciences·2016·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study.
- Species:
- dog
Plain-English summary
A group of 20 dogs with itchy skin due to allergies (canine atopic dermatitis) underwent a new treatment called rush sublingual immunotherapy (SLIT), where they received allergy extracts under their tongues over a short build-up period. After six months of treatment, most dogs showed significant improvement in their symptoms, with 13 out of 17 dogs experiencing a noticeable reduction in itching and skin irritation. Only a couple of dogs had no change or worsened, but overall, the treatment was found to be safe with no serious side effects. This suggests that rush SLIT could be an effective option for managing allergies in dogs.
People also search for: dog itching treatment · canine atopic dermatitis immunotherapy · rush SLIT for dog allergies
Abstract
Twenty dogs with canine atopic dermatitis (CAD) were treated with rush sublingual immunotherapy (SLIT), with a 48 hour build-up phase and 6 months maintenance phase (treated by antigen once every 3-4 weeks). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (baseline) and after 6 months. An open, non-controlled, non-randomized pilot trial was conducted to assess the effectiveness and safety of rush SLIT for environmental allergen extracts (Dematophagoides pteronyssinus and D.farinae mix and other). Three dogs dropped out and 17 dogs finished the trial. CADESI-4 at baseline was 60.6±27.1 (range 17-107, n=17). After 6 months of SLIT treatment, CADESI-4 was 37.4±36.0 (range 5-152, n=17) (p<0.01), which was a 38.3% reduction. A significant improvement, defined as a CADESI-4 reduction of >30%, was observed in 13 out of 17 dogs (76%). A moderate improvement, defined as a CADESI-4 reduction of ≦30%, was observed in 2 dogs (12%). In the other 2 dogs (12%), CADESI-4 worsened or showed no change. However, no severe adverse effects were observed during the trial. Therefore, rush SLIT against environmental allergen extract for CAD showed effectiveness and safety as evidenced by the reduction of CADESI-4 after 6 months SLIT without severe adverse effects.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27096781/